Rare X chromosome abnormalities in systemic lupus erythematosus and Sjögren's syndrome by Sharma, Rohan et al.
 
 
University of Birmingham
Rare X chromosome abnormalities in systemic
lupus erythematosus and Sjögren's syndrome
Sharma, Rohan; Harris, Valerie M; Cavett, Joshua; Kurien, Biji T; Liu, Ke; Koelsch, Kristi A;
Fayaaz, Anum; Chaudhari, Kaustubh S; Radfar, Lida; Lewis, David; Stone, Donald U;
Kaufman, C Erick; Li, Shibo; Segal, Barbara; Wallace, Daniel J; Weisman, Michael H;
Venuturupalli, Swamy; Kelly, Jennifer A; Pons-Estel, Bernardo; Jonsson, Roland
DOI:
10.1002/art.40207
License:
Other (please specify with Rights Statement)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Sharma, R, Harris, VM, Cavett, J, Kurien, BT, Liu, K, Koelsch, KA, Fayaaz, A, Chaudhari, KS, Radfar, L, Lewis,
D, Stone, DU, Kaufman, CE, Li, S, Segal, B, Wallace, DJ, Weisman, MH, Venuturupalli, S, Kelly, JA, Pons-Estel,
B, Jonsson, R, Lu, X, Gottenberg, J-E, Anaya, J-M, Cunninghame-Graham, DS, Huang, AJW, Brennan, MT,
Hughes, P, Alevizos, I, Miceli-Richard, C, Keystone, EC, Bykerk, VP, Hirschfield, G, Xie, G, Nordmark, G,
Bucher, SM, Eriksson, P, Omdal, R, Rhodus, NL, Rischmueller, M, Rohrer, M, Wahren-Herlenius, M, Witte, T,
Alarcon-Riquelme, M, Mariette, X, Lessard, CJ, Harley, JB, Ng, W-F, Rasmussen, A, Sivils, KL & Scofield, RH
2017, 'Rare X chromosome abnormalities in systemic lupus erythematosus and Sjögren's syndrome', Arthritis &
Rheumatology (Hoboken). https://doi.org/10.1002/art.40207
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
This is the peer reviewed version of the following article: Sharma, R., et.al, Rare X chromosome abnormalities in systemic lupus
erythematosus and Sjögren's syndrome. Arthritis & Rheumatology. Accepted Author Manuscript. doi:10.1002/art.4020, which has been
published in final form at 10.1002/art.4020. This article may be used for non-commercial purposes in accordance with Wiley Terms and
Conditions for Self-Archiving.
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
 Rare X chromosome abnormalities in systemic lupus erythematosus and Sjögren’s syndrome 
 
Rohan Sharma, MBBS1,3,4, Valerie M. Harris, MS1,2,3, Joshua Cavett, MS1,3, Biji T. Kurien, PhD1,3,4, Ke Liu, 
BS5,6 , Kristi A. Koelsch, PhD1,3,4, Anum Fayaaz, MBBS4, Kaustubh S. Chaudhari, MBBS4 , Lida Radfar, DDS7, 
David Lewis, DDS7, Donald U. Stone, MD8, C. Erick Kaufman, MD3, Shibo Li, MD9, Barbara Segal, MD10, 
Daniel J. Wallace, MD11, Michael H. Weisman, MD11, Swamy Venuturupalli, MD11, Jennifer A. Kelly, 
MPH1, Bernardo Pons-Estel, MD12,  Roland Jonsson, DMD, PhD13,14,  Xianglan Lu, PhD9, Jacques-Eric 
Gottenberg, MD, PhD15, Juan-Manuel Anaya MD, PhD16, Deborah S. Cunninghame-Graham, PhD17, 
Andrew J.W. Huang, MD, MPH18, Michael T. Brennan, DDS, MHS19, Pamela Hughes, MD, PhD 18, Ilias 
Alevizos, DMD, MMSc20,  Corinne Miceli-Richard, MD, PhD21, Edward C. Keystone, MD22, Vivian P. 
Bykerk, MD23, Gideon Hirschfield, PhD24, Gang Xie, PhD25, Gunnel Nordmark, MD, PhD26, Sara 
Magnusson Bucher, MD27, Per Eriksson, PhD28, Roald Omdal, MD, PhD29, Nelson L. Rhodus, MPH, DDS30, 
Maureen Rischmueller, MBBS31,32, Michael Rohrer, DDS18, Marie Wahren-Herlenius, MD, PhD33, Torsten 
Witte, MD34, Marta Alarcon-Riquelme, MD, PhD35, Xavier Mariette, MD, PhD21, Christopher J. Lessard, 
PhD1, John B. Harley, MD, PhD5,6,36, Wan-Fai Ng, PhD37, Astrid Rasmussen, MD, PhD1, Kathy L. Sivils, 
PhD1,2, and R. Hal Scofield, MD1,2,3,4 
 
1Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma 
City, OK, USA; Departments of 2Pathology and 3Medicine, College of Medicine, University of Oklahoma 
Health Sciences Center, Oklahoma City, OK, USA; 4Medical Service, Department of Veterans Affairs 
Medical Center, Oklahoma City, OK, USA; 5Center for Autoimmune Genomics and Etiology (CAGE), 
Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; 6College of Medicine, University of 
Cincinnati, Cincinnati, Ohio, USA; 7Department of Oral Diagnosis and Radiology, College of Dentistry, 
Brief Report Arthritis & Rheumatology
DOI 10.1002/art.40207
This article has been accepted for publication and undergone full peer review but has not been
through the copyediting, typesetting, pagination and proofreading process which may lead to
differences between this version and the Version of Record. Please cite this article as an
‘Accepted Article’, doi: 10.1002/art.40207
© 2017 American College of Rheumatology
Received: Sep 25, 2016; Revised: Apr 10, 2017; Accepted: Jul 06, 2017
This article is protected by copyright. All rights reserved.
2 
 
University of Oklahoma Health Sciences Center, Oklahoma City, USA; 8Department of Ophthalmology, 
Johns Hopkins University, Baltimore, MD, USA, and King Khaled Eye Specialist Hospital, Riyadh, KSA; 
9Department of Pediatrics, College of Medicine, University of Oklahoma Health Sciences Center, 
Oklahoma City, OK 73104, USA; 10Department of Medicine, University of Minnesota Medical School, 
Minneapolis, MN, USA; 11Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA; 
12Sanatorio Parque, Rosario, Argentina;; 13Broegelmann Research Laboratory, Department of Clinical 
Science, University of Bergen, Bergen 5021, Norway; 14Department of Rheumatology, Haukeland 
University Hospital, Bergen 5021, Norway; 15Strasbourg University, Strasbourg, France; 16Center for 
Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del 
Rosario, Bogota, Colombia; 17Division of Genetics and Molecular Medicine and Division of Immunology, 
Infection and Inflammatory Disease, King’s College London, London, UK; 18Department of 
Developmental and Surgical Sciences, University of Minnesota, Minneapolis, MN, USA; 19Department of 
Oral Medicine, Carolinas Medical Center, Charlotte, NC 28232, USA; 20Molecular Physiology & 
Therapeutic Branch, National Institute of Dental and Craniofacial Research, Bethesda, MD, , USA; 
21Department of Rheumatology, Université Paris-Sud, AP-HP, INSERM U1012, Le Kremlin-Bicêtre, France; 
22Department of Medicine, Mount Sinai Hospital and University of Toronto, Toronto, Ontario; 23Hospital 
for Special Surgery, New York, USA; 24NIHR Biomedical Research Unit, University of Birmingham, 
Birmingham, UK; 25Samuel Lunenfeld and Toronto General Research Institutes, Departments of 
Medicine, Immunology and Molecular Genetics, University of Toronto, Toronto Ontario; 26Section of 
Rheumatology, Department of Medical Sciences and Science for Life Laboratory, Uppsala University, 
Uppsala, Sweden; 27Department of Rheumatology, Örebro University Hospital, Örebro, Sweden; 
28Rheumatology, Department of Clinical and Experimental Medicine, Linköping University, Linköping, 
Sweden; 29Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, 
Stavanger, Norway; 30Department of Diagnostic and Biological Sciences, School of Dentistry, University 
This article is protected by copyright. All rights reserved.
3 
 
of Minnesota, Minneapolis, USA; 31Rheumatology Department, The Queen Elizabeth Hospital, Woodville 
South, SA 5011, Australia; 32Discipline of Medicine, University of Adelaide, Adelaide, SA 5000, Australia; 
33Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; 34Clinic for 
Immunology and Rheumatology, Hannover Medical School, 30625 Hannover, Germany; 35Medical 
Genomics, Centre for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-
Andalusian Regional Government, Health Sciences Technology Park, Granada 18016, Spain and     
Unit for Chronic Inflammatory Diseases, IMM, Karolinska Institutet, Stockholm, 17177, Sweden; 
36Medical Service, Department of Veterans Affairs Medical Center, Cincinnati, Ohio, USA; 
37Musculoskeletal Research Group, Institute of Cellular Medicine & NIHR Newcastle Biomedical Research 
Centre, Newcastle University, Newcastle upon Tyne, United Kingdom; 
 
Correspondence to: 
Hal Scofield 
825 NE 13th Street 
Oklahoma City, OK 73104 
Phone +1 405 271 7774 
Fax +1 405 271 4110 
Email hal-scofield@omrf.ouhsc.edu 
  
This article is protected by copyright. All rights reserved.
4 
 
Abstract 
 
Background. Sjögren’s syndrome and systemic lupus erythematosus (SLE) are related by clinical and 
serological manifestations as well as genetic risks.  Both diseases are more commonly found in women 
compared to men at a ratio of about 10 to 1.  Common X chromosome aneuploidies, 47,XXY and 47,XXX, 
are enriched among men and women, respectively, in either disease suggesting a dose effect on the X 
chromosome. 
Methods.  We examined cohorts of Sjögren’s syndrome or SLE patients with intensity plots of X 
chromosome single nucleotide polymorphism (SNP) alleles along with karyotype of selected subjects. 
Results.  Among ~2500 women with SLE we found three patients with a triple mosaic consisting of 
45,X/46,XX/47,XXX.  Among ~2100 women with Sjögren’s syndrome, one patient had 45,X/46,XX/47,XXX 
with a triplication of the distal p arm of the X chromosome in the 47,XXX cells.  Neither the triple mosaic 
nor the partial triplication were found among controls.  In another Sjögren’s cohort, we found a mother-
daughter pair with partial triplication of this same region of the X chromosome. The triple mosaic occurs 
in approximately 1 in 25,000 to 50,000 live female births, while partial triplications such are even rarer. 
Conclusions.   Very rare X chromosome abnormalities are present among patients with either Sjögren’s 
or SLE, and may inform the location of a gene(s) that mediate an X dose effect as well as critical cell 
types in which such effect is operative.   
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Introduction 
 
Systemic lupus erythematosus (SLE) and Sjögren’s syndrome are related by common autoimmune 
serology, clinical manifestations, and genetics, as well as a strong bias towards the female sex.  The sex 
bias for SLE is about 10-to-11, 2, while among those with Sjögren’s, women are over-represented 
between 10 and 15-fold.3   
 
Aneuploidies of the X chromosome are common in the human population.  Klinefelter’s syndrome (male 
47,XXY) occurs in about 1 in 500 live male births but 80% of these men are undiagnosed.4 Meanwhile, 
47,XXX is found in about 1 in 1000 live born girls with only about 1% identified.5, 6 We have found excess 
47,XXY among men with either SLE7, 8 or Sjögren’s syndrome9 as well as excess 47,XXX among women 
with these diseases.10  On this basis, we have proposed an X chromosome dose effect for the sex bias of 
SLE and Sjögren’s syndrome.  Such a bias might be mediated by specific genes that escape X inactivation, 
global escape of X inactivation in specific cell types11 or interference with immune tolerance by 
increased production of X chromosome gene products12, or an effect on the immune system by the 
mosaicism of random X inactivation.13   
 
We have previously reported a 46,XX man among 316 men with SLE.14 This X chromosome abnormality 
occurs in as few as 1 in 25,000 to 1 in 50,000 live born boys.  We undertook the present study to 
examine women with either SLE or Sjögren’s syndrome for rare X chromosome aneuploidies. 
 
Methods 
Subjects.  We studied a large cohort of SLE patients with about 60% being of European heritage and 40% 
of African heritage, gathered for genetic and other studies, which has been described in detail15 as well 
as a large cohort of primary Sjögren’s syndrome patients, where all subjects meeting criteria for other 
This article is protected by copyright. All rights reserved.
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autoimmune rheumatic disease (that is, those with secondary Sjögren’s were excluded).16, 17 Subjects 
met the respective research classification criteria for each of the diseases.18, 19  Women demonstrated to 
not have SLE or Sjögren’s served as controls.  As previously described10, controls were screened for 
autoimmune rheumatic disease, and no such disease was identified.  
 
X chromosome Analyses: The subjects were screened for X chromosome abnormalities by examination 
of intensity plots of X chromosome single nucleotide polymorphism (SNP) alleles, as we have previously 
described.8, 10 In these displays (so-called, b plots) the fluorescent intensity of the b allele is divided by 
the intensity of the a and b alleles; thus, giving values of 1.0 for homozygous b SNPs, 0.5 for ab 
heterozygous SNPs and 0.0 for homozygous a SNPs.  However, a person with three X chromosomes will 
have b plot results at 0.33 for aab SNP alleles and 0.67 for abb alleles.  Subjects with abnormal b plots 
were then studied by karyotype of peripheral blood mononuclear cells, or florescent in situ hybridization 
(FISH), as previous described.8   Some subjects were studied directly with karyotype using standard 
methods in a Clinical Laboratory Improvements Amendments (CLIA)-approved laboratory. 
 
Statistics.  We calculated binomial 95% confidence intervals for ratios.  To calculate the prevalence of 
SLE among individuals with X triple mosaic, we used Bayes’ theorem as previously described.8 Briefly, 
P(B/A) = P(A/B) x P(B)/PA), where P(B/A) = prevalence of SLE among those with the triple mosaic, P(A/B) 
= prevalence of the triple mosaic among SLE patients, P(B) = prevalence of SLE in the population, and 
P(A) = prevalence of the X triple mosaic in the population.     
 
Results 
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Among 2,426 women with SLE, we found three with the rare triple mosaic of 45,X/46,XX/47,XXX based 
on the b plots; these results were confirmed by G-band karyotyping of 50 cells (Table 1). These SLE 
patients had approximately the same ratio of cells with the abnormal X chromosome number.  Namely, 
only 3% of cells were either 45,X or 47,XXX, while a large majority (~94%) carried 46,XX.  In examination 
of their clinical records, there was no diagnosis nor clinical evidence of Turner’s syndrome, abnormal 
sexual development, or infertility.  Binomial 95% confidence intervals for the ratio 3 in 2,426 (0.0012 or 
1 in 809) were 0.0003 to 0.0036 (or 1 in 3333 to 1 in 278).  And, therefore, did not include the estimated 
birth rate of 45,X/46,XX/47,XXX of 1 in 25,000.5, 20, 21  Thus, we concluded that there is a statistical 
increase in the prevalence of the X chromosome triple mosaic among SLE patients.   
 
We used Bayes’ theorem to calculate the prevalence of SLE among women carrying the X triple mosaic.  
For this calculation we assumed a prevalence for SLE of 1 in 1000 along with a prevalence of the X triple 
mosaic of 1 in 25,000.  The calculation predicted that 1 in 32 individuals with 45,X/46,XX/47,XXX will 
have SLE.      
 
Among 2138 women with Sjögren’s syndrome we did not find a subject with the X chromosome triple 
mosaic described above.  Instead, when examining X chromosome b plots, we noted a single subject 
with a partial triplication of the X chromosome p arm.  That is, distal Xp showed 4 intensity bands at 0.0, 
0.3, 0.6 and 1.0, indicating three copies of this portion of the X chromosome, but other areas of the X 
chromosome showed only three bands at 0.0, 0.5 and 1.0.  The latter is the pattern for two X 
chromosomes (Figure 1A).  We obtained a blood sample from this subject and performed karyotyping, 
which showed a triple X chromosome mosaic with 2 of 20 (10%) cells examined carrying 45,X and 13 of 
20 (65%) cells carrying 46,XX, while 5 of 20 (25%) of cells had a triplication of the distal portion of the p 
arm of X (see Figure 1B).  This additional, triplicated portion of X consisted of a non-reciprocal 
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translocation on to one of the X chromosomes, that is, 47,XX+Xp.  By karyotype this abnormality was 
designated 45,X/46,XX/46,X,der(X)(pter>q28::p11.4>pter) (Figure 1).  
 
We have identified another Sjögren’s patient with a rare X chromosome abnormality in a United 
Kingdom Sjögren’s cohort. The patient was studied by karyotype as a child based on the presence of 
epilepsy, oligomenorrhea, and thyroid dysfunction.  This study showed one normal X chromosome and 
one isochrome Xp, that is, an X chromosome with 2 p arms (Figure 1C).  Her mother had an inverted 
segment of Xq (Figure 1C).  Both the mother and daughter have Sjögren’s syndrome.  This entire cohort 
of 940 Sjögren’s patients has not been systematically studied for X chromosome abnormalities as 
approximate 700 are included among the 2138 studied above.  So, while the identification of this partial 
triplication of Xp must be considered anecdotal, the triplicated region overlaps with the one found 
among the systematically studied patients (Figure 1C).  Thus, this incidentally found X chromosome 
abnormality supports the idea that a gene or genes within distal Xp mediate the X chromosome dose 
effect. 
 
We found no control subject (n=2712) with the X chromosome triple mosaic, or any variant thereof 
(Table 1). 
 
Discussion 
 
SLE and Sjögren’s syndrome, similar to many other autoimmune diseases, have a marked sex bias with 
women affected about 10 times more often than men.  A number of hypotheses have been proposed, 
and some of these tested, to explain the marked sex bias in these diseases.  An obvious difference is sex 
hormones, which might include not only estrogen, androgen and progesterone but also prolactin.22 
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Several estrogenic effects, including differentiation of T helper cells, induction of interferon, and survival 
of B cells, may predispose to autoimmune disease23 as well as recently described effects on the AIRE 
gene.24  A counterargument to the hormone hypothesis is that sex hormones are within normal limits at 
the time of SLE diagnosis25, 26 and are not different between men with SLE and men with other chronic, 
non-autoimmune disease.27  However, men with untreated hypogonadism are reported to be at high 
risk of SLE.28  There is no evidence of acquired X monosomy among women with SLE29, 30, as there is 
among those with autoimmune thyroid disease31 or primary biliary cirrhosis.32 
 
Failure to inactivate an X chromosome in activated CD4+ T cells is found in SLE patients33-35 and lupus-
prone mice36 with failure to methylate; and, thus silence, X-linked immune genes.37 A recent study has 
shown a global difference in X chromosome inactivation in resting lymphocytes, which was associated 
with bi-allelic expression of genes from lymphocytes of SLE patients.11  Others have proposed that an 
overall effect of X reactivation might perturb immune tolerance.12  Each of these proposed mechanism 
might underlie a gene dose effect on the X chromosome, which might involve one or more immune-
related proteins encoded on the X chromosome. 
 
We have found very rare X chromosome abnormalities among patients with either SLE or Sjögren’s 
syndrome.  Based on karyotypes of consecutive live births,5, 20, 38 the 45,X/46,X/47,XXX triple mosaic is 
found in about in 1 in 25,000 live born girls, but was present in about 1 in 800 women with SLE. We did 
not find and did not expect to find the rare triple mosaic among our controls, which number only just 
above 2000.  But, past studies of more than 25,000 live female births5, 21, 38 serve as an external 
validation of the incidence and prevalence of the 45,X/46,XX/47,XXX mosaic.  Meanwhile, the 
45,X/46,XX/47,XX+Xp found in one of our Sjögren’s syndrome patients is nearly unprecedented.39  
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Finding these X chromosome rarities has several implications.  For instance, only a small percentage of 
cells carried the additional X or portion of the X chromosome in these patients.  The data from Wang, et 
al. are consistent with this finding as the unusual maintenance of X chromosome inactivation in 
lymphocytes leads to bi-allelic expression of X-linked genes in only a few cells.11 In addition, similar to 
those with 100% of cells carrying 47,XXX10, the 4 patients we described have no evidence of abnormal 
sex hormones or sexual development.  Likewise, hormonal imbalance due to Turner’s syndrome, which 
is likely under-represented among SLE patients7, is not expected with the low proportion of 45,X cells in 
our patients. Thus, estrogen, progesterone, or androgen differences cannot be evoked as an explanation 
of the apparent association of the X triple mosaic with SLE and Sjögren’s syndrome.   
 
Despite the associations we find, increased prevalence of these rare X chromosome aneuploidies does 
not prove causality.  Nonetheless, given the rarity of these X chromosome abnormalities, association by 
chance alone seems unlikely to us. Determining mechanism by which additional X chromosomes or 
distal Xp fragments, increase the risk of these diseases remains to be determined, but will provide 
evidence of causality.  Perhaps the findings reported herein give important clues, which can be used to 
direct and narrow the candidates for genes impacting the X chromosome dose effect.  The distal p arm 
of the X chromosome contains multiple genes that escape X inactivation.11 Thus, the finding of a partial 
trisomy of this portion of the X chromosome in these patients suggests, but does not prove, that the 
gene or genes mediating this effect are found in this region.  There are a number of past examples in 
which identification of an abnormality on karyotype in an affected individual led to much more rapid 
identification of the genetic cause of a particular disease.  These include Duchenne’s and Becker’s 
muscular dystrophy, Angelman’s syndrome, and fragile X syndrome.  But, perhaps relevant to the 
findings herein, was the identification of a chromosome X-21 balanced transloction in a girl with 
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11 
 
Duchenne’s muscular dystrophy.  This finding gave the location of the gene on the X chromosome long 
before identification was possible through reverse genetics studies.40    
 In summary, we suspect that these SLE and Sjögren’s with X chromosome abnormalities inform 
greatly about the common situation, that is, the marked sex bias between 46,XX women and 46,XY men.  
Future studies, using the localization provided by the very rare patients reported herein, may be able to 
concentrate on genes within this shared triplicated region of Xp as the mediators of the X chromosome 
dose effect for sex bias in SLE and Sjögren’s syndrome.  
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Figure 1.  A. B plot of the X chromosome of a Sjögren’s syndrome patient.  The distal aspect of the p arm 
demonstrates a 4-band pattern consistent with three copies of this portion of the X chromosome while 
the centromeric half of Xp and Xq demonstrate a 3-band pattern consistent with two copies of these 
portions of the X chromosome. B. A karyotype of the X chromosome of all three cells types found in the 
Sjögren’s patient.   One normal X chromosome was found in 10% of cells (B, left), two normal X 
chromosomes were found in 65% of cells (B, middle), and one normal X chromosome along with an X 
chromosome with a non-reciprocal translocation of distal Xp was found in 25% of cells (B, right).  The 
arrow shows the junction of Xq with the translocated distal Xp.  Cytogenetic designation is given for this 
patient’s X chromosome complement.  C.  Diagram of the X chromosome abnormalities found.  A normal 
X is shown on the far left, the pSS-affected mother  
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Table 1.  Patients with an X chromosome triple mosaic were identified in SLE and Sjögren’s syndrome 
cohorts.  The estimated birth rate for the triple mosaic (45,X/46,XX/47,XXX) is 1 in 25,000 to 50,000 live 
female births.   
 
   Total  X triple mosaic  Binomial 95% CI 
______________________________________________________________________  
SLE   2426   3  1 in 278 to 1 in 3333* 
Sjögren’s  2138   1  1 in 385 to 1 in 100,000 
Combined  4564   4  1 in 1111 to 1 in 5000* 
Controls  2712   0  NA 
________________________________________________________________________ 
* Neither 95% CI cross the known birth rate of 45,X/46,XX/47,XXX; and, thus, demonstrate  
a statistically significant result.  NA- not applicable  
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Figure 1.  A. B plot of the X chromosome of a Sjögren’s syndrome patient.  The distal aspect of the p arm 
demonstrates a 4-band pattern consistent with three copies of this portion of the X chromosome while the 
centromeric half of Xp and Xq demonstrate a 3-band pattern consistent with two copies of these portions of 
the X chromosome. B. A karyotype of the X chromosome of all three cells types found in the Sjögren’s 
patient.   One normal X chromosome was found in 10% of cells (B, left), two normal X chromosomes were 
found in 65% of cells (B, middle), and one normal X chromosome along with an X chromosome with a non-
reciprocal translocation of distal Xp was found in 25% of cells (B, right).  The arrow shows the junction of Xq 
with the translocated distal Xp.  Cytogenetic designation is given for this patient’s X chromosome 
complement.  C.  Diagram of the X chromosome abnormalities found.  A normal X is shown on the far left, 
the pSS-affected mother  
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